InsideArbitrage Event Driven Monitor – April 17, 2023
Quick updates on the event driven strategies we follow on InsideArbitrage.
Subscribe to receive our Event Driven Monitor by email every morning before the market opens.
Merger Arbitrage
- Prometheus Biosciences (RXDX) to be acquired by Merck & Co. (MRK) for $8.33 billion or $200 per share in cash.
- According to Reuters, The Federal Reserve’s Board of Governors approved UBS Group AG’s (UBS) acquisition of the U.S. subsidiaries of Credit Suisse (CS), clearing another major hurdle for the completion of the Swiss-brokered rescue deal.
- Pfizer (PFE) filed a briefing paper with the European Commission concerning its merger with Seagen (SGEN).
Only plus or premium subscribers can access this post. Subscribe today.
